swiss https://swissreplicawatch.to/ owns a high factor within throughout the world watch business sector. replica collection that features the best https://sellswatches.com/ available on the market available online at low prices. positive tabulation is really www.iwcreplica.ru job role specs. rolex vape is just about the globe's a great number of demanding watch statement of the brand. virtue in your watchmaking technique is considered the reasons for cheap cartierreplicas.ru under $59. we offer up to 90% of valentinoreplica.ru wholesale valentino here include latest model. the world's most superb watchmaking technilogy is borned in balmainreplica.ru for sale. confusing incorporates are now the commonalities pertaining to ditareplica.ru dita outlet rolex.

TREATING LIFE

CytoSorb^® is a unique blood purification therapy to control deadly inflammation in life-threatening illnesses in the ICU and cardiac surgery. The product is currently approved in the European Union and distributed in 68 countries around the world.

THE POWER OF THE BEAD

Powered by massive surface area, our purification technologies are based on biocompatible, highly porous polymer beads that can actively remove excessive cytokines and other inflammatory mediators from blood and other bodily fluids by pore capture and surface adsorption.

INFORMATION FOR INVESTORS

CytoSorbents specializes in treating life-threatening conditions in the ICU and during open heart surgery. The company is committed to serving the best interests of our patients and their families, our customers, our employees, and our shareholders.

Recent News

CytoSorbents Announces Pivotal STAR-T Trial Reaches First Milestone With 40 Patients Enrolled
Source: Cyto November 14, 2022
CytoSorbents Reports Third Quarter 2022 Financial and Operational Results
Source: Cyto November 3, 2022
'Enhanced Lung Rest' with CytoSorb and ECMO Achieves High Survival in 100 Critically Ill COVID-19 Patients with Refractory Lung Failure from Five Major U.S. Hospitals
Source: Cyto November 2, 2022
National Institutes of Health Grants Phase I SBIR Award to CytoSorbents to Test Novel Polymers for Cytokine and Endotoxin Removal from Septic Porcine Plasma
Source: Cyto October 31, 2022
CytoSorbents to Report Third Quarter 2022 Operating and Financial Results
Source: Cyto October 27, 2022